Fast Five Quiz: Multiple Myeloma Management

Joshua Richter, MD; Emmanuel C. Besa, MD

January 11, 2022

The antibody component of the drug class known as antibody-drug conjugates is directed against B-cell maturation agent (BCMA), a protein that is expressed on normal B lymphocytes and multiple myeloma cells. The small molecule component of this conjugate is monomethyl auristatin F (MMAF), a microtubule inhibitor.

When the antibody-drug conjugate binds to BCMA, the conjugate gets internalized and releases MMAF, leading to cell cycle arrest and apoptosis. It also results in tumor cell lysis though antibody-dependent cellular toxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP).

Learn more about antibody-drug conjugates in multiple myeloma.

1 2 3 4 5 6

Next Section

Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.

Cite this: Joshua Richter, Emmanuel C. Besa. Fast Five Quiz: Multiple Myeloma Management - Medscape - Jan 11, 2022.

Comments

Commenting is limited to medical professionals. To comment please Log-in.

Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.